Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiao Pi granule to prevent recurrence and metastasis of triple-negative breast cancer
ChiCTR2200057031Phase 4Completed
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in triple-negative breast cancer (TNBC) comparing Xiao Pi granule with Placebo (2 arms). Primary endpoints: CXCL-1 cytokine secreted by tumor-associated macrophages (TAMs) in blood and Quality of life. Started Oct 2018; status: completed.
02
Drugs
Xiaopi Granule
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2200057031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057031.